Notícias

Wegovy captured about 89% of weekly prescriptions.

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.3% and the

Oral Wegovy is now cleared in all EU member states.

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State

Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.

BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.

The milestone payment strengthens VivoSim’s cash position while management projects significant revenue growth driven by expanding demand for its human-based preclinical testing platform. Key Investor TakeawaysVivoSim (NASDAQ:VIVS) received a $5 million milestone payment from Eli Lilly tied to the advancement of a previously sold drug candidate into Phase 2 studies.

Management jacked up its forecast in a way that's impossible to ignore, and while the stock has already ripped higher, the real debate is whether this is a new reality or a temporary sugar high.

(Bloomberg) -- AdvanCell Pty, a biotechnology firm backed by Eli Lilly & Co., has raised $315 million in new funding, underscoring investor confidence in its experimental cancer therapy.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsTrump Drops 20% Fee for Hormuz Cargo After Gulf PressureUS Hits Iran With Strikes, Blockade as Trump Plans Hormuz ChargeOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI Companion‘We Faltered’: IBM Plunges M

FDA grants full approval to Eli Lilly's selpercatinib (Retevmo) for a wider group of adult and pediatric patients with RET fusion solid tumors. The decision shifts selpercatinib from accelerated to traditional approval and broadens its labeled use across multiple tumor types. The update reinforces Eli Lilly's (NYSE:LLY) position in oncology and opens new commercial and clinical avenues for the drug. Eli Lilly, known for its oncology and biopharma portfolio, now has a fully approved RET...

Since its obesity pill Foundayo hit the market in April, Lilly has captured about 11% of the prescription volume for new pills, according to the latest weekly data. Novo Nordisk’s Wegovy pill, which launched in January, commands the rest. It is a remarkable turn of events for the near $80 billion anti-obesity market, among the hottest in the industry.

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -2.48% change compared to its last close.

Eli Lilly and Company (LLY) on Tuesday received traditional approval from the US Food and Drug Admin

The presentation on Biogen’s experimental Alzheimer’s treatment at a medical meeting Tuesday was supposed to boost confidence in its drug’s prospects. Instead, Biogen stock is down 6%, to $197. Tuesday’s presentation on the drug diranersen, at London’s Alzheimer’s Association International Conference, left attendees confused about what to conclude from Biogen’s Phase 2 study known as CELIA.

In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.

BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.

While the company's AI spending commands attention, the real story is how the technology is already accelerating the core business that funds it all.

The company attributed the guidance cut to a larger-than-expected shift in payer mix and a greater financial impact from health insurance exchanges.

JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.

Eyes are on the rollout of Lilly's new weight loss pill.

Madrigal Pharmaceuticals announced earlier on Friday that it has received three new U.S. patents for its lead drug, Rezdiffra.

Eli Lilly has whipsawed shareholders in 2026, but one under-the-radar catalyst in its pipeline could change the trajectory entirely. Here is what the bulls are watching that most investors are still sleeping on.

Cathie Wood Unveils Major Portfolio Reset With SpaceX, Meta Buys and AMD Cuts

Cathie Wood's ARK Invest was extremely active last week, adding SpaceX and Meta, while selling AMD and Robinhood stock.

At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on.

Two drugs now generate almost two-thirds of the pharmaceutical giant's revenue.

Wall Street is waiting for evidence that AI can change the economics of making drugs. In the lab, AI is already delivering a tangible leap in efficiency, predicting how proteins fold, identifying potential drug targets, and screening millions of molecules virtually. Traditionally, scientists have selected drug targets largely by hand, drawing on the body of research they know best to decide which proteins might matter in a disease, then spending months or years testing those hypotheses in the lab.

This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.

There are good reasons to invest in Lilly and to hold off.

Eli Lilly plans to present new Alzheimer's research at the 2026 Alzheimer's Association International Conference, including long term data on Kisunla (donanemab-azbt). The company will share updated safety and biomarker findings from its Kisunla program. Eli Lilly will also outline progress on blood based P-tau217 diagnostics that could support broader Alzheimer's screening. Eli Lilly, traded as NYSE:LLY, is set to bring fresh Alzheimer's data to the forefront, while attention has recently...